Hedy Teppler
Overview
Explore the profile of Hedy Teppler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orkin C, Molina J, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, et al.
Lancet HIV
. 2023 Dec;
11(2):e75-e85.
PMID: 38141637
Background: In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz...
2.
Rungmaitree S, Aurpibul L, Best B, Li X, Warshaw M, Wan H, et al.
J Pediatric Infect Dis Soc
. 2023 Oct;
12(12):602-609.
PMID: 37815035
Background: IMPAACT 2014 study is a phase I/II, multicenter, open-label, nonrandomized study of doravirine (DOR) co-formulated with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) as fixed-dose combination (DOR FDC) in...
3.
Melvin A, Yee K, Gray K, Yedla M, Wan H, Tobin N, et al.
J Acquir Immune Defic Syndr
. 2022 Oct;
92(2):153-161.
PMID: 36215957
Background: We studied the pharmacokinetics (PK) and safety of 100-mg doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed-dose combination (100/300/300 mg DOR FDC) treatment in adolescents with HIV-1. Methods: Adolescents ages 12...
4.
Mills A, Myers L, Raudenbush C, Vossen D, Teppler H, Miteva Y, et al.
Pediatr Infect Dis J
. 2021 Oct;
41(1):51-56.
PMID: 34694252
Background: Limited data exist regarding how medications for pediatric use can be developed to minimize medication errors. The integrase inhibitor raltegravir was developed for use in neonates (≥2 kg). Anticipating...
5.
Teppler H, Bautista O, Flores S, McCauley J, Luxembourg A
Contemp Clin Trials
. 2021 Apr;
105:106403.
PMID: 33857679
HPV vaccines are widely licensed as two-dose regimens, 6-12 months apart, for adolescents. Extended intervals between doses may be necessary due to resource constraints or vaccination program disruption. This international,...
6.
Nelson M, Winston A, Hill A, Mngqibisa R, Bassa A, Orkin C, et al.
AIDS
. 2021 Feb;
35(5):759-767.
PMID: 33587439
Objective: Doravirine is an alternative treatment option for individuals who do not tolerate efavirenz. We assessed efficacy, safety, and CNS effects in adults with HIV-1 and CNS complaints who switched...
7.
Orkin C, Squires K, Molina J, Sax P, Sussmann O, Lin G, et al.
Clin Infect Dis
. 2020 Dec;
73(1):33-42.
PMID: 33336698
Background: Doravirine (DOR) is a nonnucleoside reverse-transcriptase inhibitor. In the phase 3 DRIVE-AHEAD trial in treatment-naive adults with human immunodeficiency virus type 1 (HIV-1) infection, DOR demonstrated noninferior efficacy compared...
8.
Clarke D, Lommerse J, Acosta E, Cababasay M, Wang J, Spector S, et al.
J Acquir Immune Defic Syndr
. 2020 Sep;
85(5):626-634.
PMID: 32925360
Background: HIV treatment of neonates requires identifying appropriate antiretroviral dosing regimens. Our aims were to characterize raltegravir elimination kinetics in low birth weight (LBW) neonates after maternal dosing and to...
9.
Krogstad P, Samson P, Acosta E, Moye J, Townley E, Bradford S, et al.
J Pediatric Infect Dis Soc
. 2020 May;
10(2):201-204.
PMID: 32448902
Clinical Trials Registration: NCT01751568.
10.
Clarke D, Acosta E, Cababasay M, Wang J, Chain A, Teppler H, et al.
J Acquir Immune Defic Syndr
. 2020 Jan;
84(1):70-77.
PMID: 31913995
Background: Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor available in a granule formulation suitable for...